Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.
Susceptibility to moxifloxacin, penicillin and erythromycin was determined for 592 invasive Streptococcus pneumoniae collected from 20 English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) during 2003. Resistance to moxifloxacin, penicillin and erythromycin was observed in 0.8%, 5.4% and 13% of the isolates, respectively. These results show that the large majority of pneumococci were susceptible to moxifloxacin in 2003, the year when it was licensed for clinical use in the UK.
Johnson
Alan P
AP
Department of Healthcare-Associated Infection and Antimicrobial Resistance, Communicable Disease Surveillance Centre, HPA Centre for Infections, Colindale, London NW9 5EQ, UK. Alan.Johnson@hpa.org.uk
Lamagni
Theresa L
TL
Wale
Martin
M
Cavendish
Sue
S
Bishop
Louise
L
Alhaddad
Neelam
N
Warner
Marina
M
Livermore
David M
DM
Duckworth
Georgia
G
George
Robert C
RC
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D004739:England; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D007297:Inpatients; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D010406:Penicillins / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D010406:Penicillins; D011804:Quinolines; D004917:Erythromycin; D000077266:Moxifloxacin